Drug Product Impurity Characterization Detailed In CMC Draft Guidance
This article was originally published in The Tan Sheet
Executive Summary
All expected drug product impurities should be disclosed in NDAs and ANDAs, even if they are not considered sufficiently important to affect the drug's approvability, according to a new FDA draft guidance